GCL Monthly Fact Sheet January 2024

Geiger Counter Ltd
23 February 2024
 

 

NCIM - Geiger Counter Ltd - Fund Page

 

Geiger Counter Limited Plc 

 

Monthly Investor Report - January

 

The full monthly factsheet is now available on the Company's website and a summary can be found below. 

 

NCIM - Geiger Counter Ltd - Fund Page for Geiger Counter Ltd

 

Enquiries: 

 

For the Investment Manager 

CQS (UK) LLP 

Craig Cleland 

0207 201 5368 

  

For the Company Secretary and Administrator 

BNP Paribas S.A., Jersey Branch 

Dean Plowman/Ann-Marie Pereira 

01534 813 967/ 01534 709198 

 

----------------------------------------------------------------------- 

 

 

Fund Description 

 

The objective of the Geiger Counter Fund is to provide investors with the potential for capital growth through investment primarily in the securities of companies involved in the exploration, development and production of energy, predominantly within the uranium industry. Up to 30% of the value of the Company's investment portfolio may be invested in other resource-related companies from outside the energy sector.

 

Portfolio Managers 

 

Keith Watson and Robert Crayfourd 

 

 

Key Advantages for the Investor 

·      Access to mining assets in the uranium sector

·      May benefit from embedded subscription share

·      Low correlation to major asset classes

 

 

Key Fund Facts1 

 

 

Total Gross Assets 

£116.7m 

Reference Currency 

GBP 

Ordinary Shares: 


  Net Asset Value 

78.38p 

  Mid-Market Price         

62.00p 

Net gearing4 

13.50% 

Discount 

(20.90%) 

 

 

Ordinary Share and NAV Performance2 

 

 

One Month 

Three Months 

One Year 

Three Years 

Five Years 

 

(%) 

(%) 

(%) 

(%) 

(%) 

NAV 

16.86 

20.88 

48.08 

222.02 

322.99 

Share Price 

14.81 

28.50 

32.62

141.25 

217.95 

 

 

Commentary3 

 

The Fund's NAV gained 16.9% in January, ahead of the Solactive Uranium Pure Play index, which gained 10.5% in sterling terms, and the uranium price closed the month up 9.3% at $100/lb. The Fund's share price lagged the NAV.

 

The world's largest Uranium producer, Kazatomprom, reduced its production guidance for 2024 by 14% to 56.6M lbs, citing a shortage of sulphuric acid as the cause. Kazatomprom accounts for 24% of global production, but this impacts their joint venture partners equally for a total of ~40% of global production.4 This added to growing concerns from utilities on their ability to contract future volumes which should continue to support pricing.

 

The Fund remains weighted to producers with little to no hedging, to benefit from the anticipated pick up in contracting volumes at better terms than prior contracting levels, such as those seen with Cameco. Cameco and Kazatomprom are still buying material on the spot market, partly as utilities are maximising their contract flexibility to take larger volumes at lower prices given the fixed price components to those contracts. We remain underweight Cameco, relative to the Solactive Uranium Pure Play Index.

 

Following the US Senate vote to ban imports of Russian nuclear material, reports suggest it is increasingly likely to be voted through the House of Representatives in the coming weeks. Russia has already warned, via the state-owned uranium trader Tenex, that it could pre-emptively act to ban trade of uranium and associated services to the US. This continues to focus Western utility fuel buyers on the requirement to secure material and further encourages the trend to increase contracting with Western-friendly suppliers, where the Fund is positioned.

 

Whilst Russia is only 7% of primary uranium mined, they do have meaningful joint ventures with Kazatomprom and therefore influence a much larger share of the market than this figure implies. Importantly, they control a large proportion of global enrichment market, over 40%, which presents fuel supply risks for Western reactors should access be cut. In 2022 the US sourced 12% of its uranium and 24% of its enrichment from Russia.5

The Company announced on 8 February 2024 that it is considering applying for admission of the Company's ordinary shares to the Specialist Fund Segment of the London Stock Exchange as a means of broadening the appeal of the Company to a wider range of shareholders.

 

Gross Leverage

(%)

Commitment Leverage

(%)

Geiger Counter Ltd 

114

114 

 

 

CQS (UK) LLP

4th Floor, One Strand, London WC2N 5HR, United Kingdom

T: +44 (0) 20 7201 6900 | F: +44 (0) 20 7201 1200

 

CQS (US), LLC

152 West 57th Street, 40th Floor, New York, NY 10019, US

T: +1 212 259 2900 | F: +1 212 259 2699

 

CQS (Hong Kong) Limited

3305 AIA Tower, 183 Electric Road, North Point, Hong Kong, China

T: +852 3920 8600 | F: +852 2521 3189

 

Tavistock Communications

18 St. Swithin's Lane, London EC4N 8AD

T: +44 20 7920 3150 | geigercounter@tavistock.co.uk

 

Sources: 1R&H Fund Services (Jersey) Limited, as at the last business day of the month indicated at the top of this report. 2R&H Fund Services Limited/DataStream, as at the last business day of the month indicated at the top of this report, total return performance net of fees and expenses based on bid prices. These include historic returns and past performance is not a reliable indicator of future results. The value of investments can go down as well as up. Please read the important legal notice at the end of this document. 3Market data sourced from Bloomberg unless otherwise stated. The Fund may since have exited some or all of the positions detailed in the commentary.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings